Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and ...
8d
Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%, but Here's What Investors Should Focus On
This immuno-driven diagnostics company, known for partnerships with Genentech and Microsoft, just reported a notable insider ...
Adaptive reported preliminary, unaudited revenue of approximately $72 million for the fourth quarter of 2025, representing a 51% increase compared to the same period in 2024. Full-year 2025 revenue ...
As of Wednesday, April 08, Adaptive Biotechnologies Corporation’s ADPT share price has surged by 10.28%, which has investors ...
SEATTLE, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into ...
Why Adaptive Biotechnologies Stock Is Back in Focus Adaptive Biotechnologies (ADPT) is drawing attention after fourth quarter 2025 results topped analyst expectations, supported by its Minimal ...
SEATTLE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into ...
Shares of Adaptive Biotechnologies (ADPT) have been strong performers lately, with the stock up 30% over the past month. The stock hit a new 52-week high of $13.52 in the previous session. Adaptive ...
In the last three months, 4 analysts have published ratings on Adaptive Biotechnologies (NASDAQ:ADPT), offering a diverse range of perspectives from bullish to bearish. The table below provides a ...
Detailed price information for Adaptive Biotechnologies Corp (ADPT-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results